Melhem Scientific Announces $1.2M Investment in Gene Editing and Aging Research

Boston, MA – [July 25, 2025] – Melhem Scientific, a leader in data-driven and interdisciplinary scientific innovation, today announced a $1.2 million commitment to support groundbreaking research in gene editing technologies, with a special focus on age-related diseases.

This strategic investment will drive the advancement of CRISPR-based methodologies to better understand and address biological aging. It reflects Melhem Scientific’s mission to unlock nature’s secrets and accelerate research that improves the quality of human life.

"Gene editing holds transformative potential in how we approach aging and chronic disease," said Nehme Gerges Melhem, President and Founder of Melhem Scientific. "Our commitment empowers the scientific community to pursue bold research that could one day delay, prevent, or even reverse age-related conditions."

The funding will support researchers, interdisciplinary teams, and data-driven platforms exploring gene therapies for age-related degeneration, regenerative medicine, and cellular repair.

Melhem Scientific continues to expand its global research collaborations, providing expertise in experimental design, data analysis, and publication support.

To learn more about this initiative or to explore partnership opportunities, visit www.melhemscientific.com.

About Melhem Scientific

Melhem Scientific is a research support organization based in Boston, Massachusetts, dedicated to empowering innovative science through expert guidance, collaborative networks, and advanced data solutions. By enabling researchers to push the boundaries of discovery, Melhem Scientific drives progress across disciplines.